Pharmaceutical intermediates
Xanomeline Intermediates
1 pharmaceutical intermediate for Xanomeline. Indication: Mental Disorders; Schizophrenia; Alzheimer's Disease.
About Xanomeline
- Originator
- Bristol Myers Squibb
- Indication
- Mental Disorders; Schizophrenia; Alzheimer's Disease
- Approved Date
- 09/26/2024
- NCE Patent
- 09/26/2029
- DS/DP
- 07/21/2030
Available intermediates
1 intermediate currently listed for Xanomeline. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 3-Chloro-4-(pyridin-3-yl)-1,2,5-thiadiazole | 131986-28-2 | / | / |
Building toward Xanomeline?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →